I suspect they heard back from the FDA and that i
Post# of 148703
Quote:
I suspect they heard back from the FDA and that is why they moved forward with engaging Syneos as the CRO at this time.
I wish this were so, HHi, but if I were writing today's PR I would have mentioned that the protocol had already been accepted instead of saying this:
Quote:
As previously announced, the Company’s final study protocol was submitted to the FDA for approval in September 2024, and CytoDyn expects to start screening patients in early 2025.